Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane vs paclitaxel as first-line therapy in metastatic HR+ breast cancer
ChiCTR-IPR-17010455Phase 4Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in breast cancer comparing Exemestane with Paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Jan 2017; status: recruiting.
02
Drugs
exemestanepaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-IPR-17010455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010455.